AffiliationCancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Manchester M20 4BX, UK. email@example.com
MetadataShow full item record
AbstractThe bryostatins are a group of novel macrocyclic lactones derived from the marine bryozoan, Bugula neritina. In vitro evidence indicates that their main mechanism of action is modulation of protein kinase C (PKC) activity. Phase I studies suggested significant antineoplastic activity against several tumor types and defined the main dose-limiting toxicity as myalgia. Bryostatin-1 has subsequently been investigated extensively in phase II clinical trials as a single agent, although trial design has been hampered by lack of human pharmacokinetic data. Results have been generally disappointing but in vitro and animal data suggests an important role for bryostatin-1 in combination with cytotoxic agents. Preliminary results of phase I studies support these observations but further work needs to be done to define the future role of the bryostatins in the clinic.
CitationThe clinical development of the bryostatins. 2002, 13 (7):673-83 Anticancer Drugs
- Bryostatin-1: a novel PKC inhibitor in clinical development.
- Authors: Kortmansky J, Schwartz GK
- Issue date: 2003
- A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study.
- Authors: Weitman S, Langevin AM, Berkow RL, Thomas PJ, Hurwitz CA, Kraft AS, Dubowy RL, Smith DL, Bernstein M
- Issue date: 1999 Sep
- The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1.
- Authors: Szallasi Z, Du L, Levine R, Lewin NE, Nguyen PN, Williams MD, Pettit GR, Blumberg PM
- Issue date: 1996 May 1
- Chemistry and clinical biology of the bryostatins.
- Authors: Mutter R, Wills M
- Issue date: 2000 Aug
- Successful treatment of murine melanoma with bryostatin 1.
- Authors: Schuchter LM, Esa AH, May S, Laulis MK, Pettit GR, Hess AD
- Issue date: 1991 Jan 15